Mandate

Vinge advised Investor in connection with the IPO of Alligator

November 23, 2016

Alligator Bioscience AB (publ) was listed on the main market of Nasdaq Stockholm with the first day of trading being 23 November 2016. The price in the initial public offering was SEK 32.50 per share, corresponding to a total value of the company’s shares of approx. SEK 2,275 million. Investor AB, through Duba AB, was one of the two selling shareholders.
 
Vinge advised Investor. The Vinge team was headed by capital markets and public M&A partner Erik Sjöman.

Related

Vinge advises Isofol Medical AB (publ) in connection with its rights issue of units

Through the rights issue of units, consisting of shares and warrants, and the exercised over-allotment issue, Isofol will receive approximately SEK 84 million and may receive an additional maximum of approximately SEK 110 million upon exercise of all warrants at the highest subscription price.
August 01, 2025

Vinge advises Oncorena in connection with share issue

Vinge advises Oncorena Holding AB in connection with a share issue of approximately SEK 133 million.
July 30, 2025

Vinge advises Karl Hedin and minority owners on the sale of AB Karl Hedin Sågverk to Vida

Vinge has advised Karl Hedin and minority shareholders in connection with the sale of AB Karl Hedin Sågverk to Vida Aktiebolag (“Vida”).
July 24, 2025